Precision Decisions to STOP-JIA
PRECISION DECISIONS IS A RESEARCH STUDY TO DISCOVER TOOLS TO PREDICT RESPONSE TO TREATMENT FOR PATIENTS WITH POLYARTICULAR JIA
Precisions Decisions is funded by the Arthritis Foundation and CARRA
Researchers and scientists have working on an exciting project called Precision Decisions to STOP-JIA. Precision Decisions is looking to develop a set of tests based on the biology of children diagnosed with pJIA that will make it possible to more accurately diagnose and treat patients with pJIA. There are three main goals of the project:
- To be able to predict which medication has the best chance of success for each child,
- To learn when is the best time to start the certain treatments in each child, and
- To be able to predict when medication is no longer needed to control pJIA.
WHO IS INVOLVED?
48 CARRA Registry sites are participating in Precision Decisions.
The Duke Clinical Research Institute (DCRI) is the coordinating center for this study.
WHY THIS IS IMPORTANT
Imagine a day when you are able to know ahead of time which medication has the best chance of working for you (or your child), based on your personal biology? This day may soon become a reality for patients with polyarticular juvenile idiopathic arthritis, or pJIA!
Currently, there are many different medications used to treat pJIA. Doctors now know that early and effective treatment leads to better long term outcomes. But there are no tools that help guide doctors on when to start or when to stop different types of medications in children diagnosed with pJIA. Therefore, it is possible that some children get over-treated and some get under-treated. Over-treating wastes time and money, and increases risks of side effects because you are exposed to medications you might not need. Under-treating lengthens the time that arthritis is active, which not only causes pain and disability, but could also lead to permanent joint damage and poor long term outcomes.
The goal of Precision Decisions is to develop a simple inexpensive tool made up of a small number of individual tests. This tool will help design personalized treatment guidelines for each individual patient, which will improve outcomes and quality of life for both the patient and family.
Precision Decisions is partnering with a clinical research study called STOP-JIA: participants in STOP-JIA will be able to give blood samples for Precision Decisions.